Wellington Management Group LLP Aligos Therapeutics, Inc. Transaction History

Wellington Management Group LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.04 - $2.14 $489,985 - $1.01 Million	-471,140 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$2.08 - $12.2 $6.43 Million - $37.7 Million	-3,090,831 Reduced 86.77%	471,140 $1.01 Million
Q4 2021 Feb 11, 2022	SELL	$11.48 - $17.69 $3.07 Million - $4.73 Million	-267,412 Reduced 6.98%	3,561,971 $42.3 Million
Q3 2021 Nov 15, 2021	SELL	$14.57 - $17.72 $5.04 Million - $6.13 Million	-346,198 Reduced 8.29%	3,829,383 $59.4 Million
Q2 2021 Aug 16, 2021	BUY	$20.3 - $33.6 $3.58 Million - $5.92 Million	176,292 Added 4.41%	4,175,581 $85.1 Million

Q1 2021 May 17, 2021	BUY	$19.1 - $34.94 $1.37 Million - $2.5 Million	71,691 Added 1.83%	3,999,289 $90.8 Million
Q4 2020 Feb 12, 2021	BUY	$13.2 - $32.74 $51.8 Million - $129 Million	3,927,598 New	3,927,598 $107 Million

46.2M

6.11M

200

Ticker ALGS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,717,000
Market Cap $13.9M
Description
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...

Get notified when there are updates to the investment portfolio of Wellington Management Group LLP, based on Form 13F filings with the SEC.

Stay updated on Wellington Management Group LLP with notifications on news.